Brain metastasis: Opportunity for drug development?

Current Opinion in Neurology

Volumn 25, Issue 6, 2012, Pages 786-794

  Preusser, Matthias ^a   Berghoff, Anna S ^a   Schadendorf, Dirk ^b   Lin, Nancy U ^c   Stupp, Roger ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c Dana Farber Cancer Center   (United States)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

brain metastases; drug; prophylaxis; treatment

Indexed keywords

AFATINIB; BETA1 INTEGRIN; BEVACIZUMAB; BUPARLISIB; CAPECITABINE; CILENGITIDE; CORTICOSTEROID; CRIZOTINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ICOTINIB; INIPARIB; IPILIMUMAB; LAPATINIB; NERATINIB; PAZOPANIB; RECOMBINANT ENDOSTATIN; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VELIPARIB; VEMURAFENIB;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BRAIN FUNCTION; BRAIN METASTASIS; BRAIN TUMOR; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PATIENT; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CEREBROSPINAL FLUID; DISTANT METASTASIS; DRUG DEVELOPMENT; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; EXTRACELLULAR MATRIX; HIGH RISK POPULATION; HUMAN; IMMUNE SYSTEM; INFLAMMATION; LEUKOENCEPHALOPATHY; LIPOPHILICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MEDICAL RESEARCH; MELANOMA; METHODOLOGY; MONOTHERAPY; NEUROLOGIC EXAMINATION; OVERALL SURVIVAL; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREMEDICATION; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOPREVENTION; DRUG DESIGN; FEMALE; HUMANS; LUNG NEOPLASMS; MELANOMA; NEOPLASMS;

EID: 84870065132     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328359320d     Document Type: Review

References (40)

1. Kamar FG, Posner JB. Brain metastases. Semin Neurol 2010; 30:217-235.
2. Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30:419-425.
3. Preusser M, Capper D, Ilhan-Mutlu A, et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 2012; 123:205-222.
4. Fidler IJ. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 2011; 21:107-112.
5. Lockman PR, Mittapalli RK, Taskar KS, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 2010; 16:5664-5678.
6. Le Pechoux C, Dunant A, Senan S, et al. Standard-dose versus higherdose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 2009; 10: 467-474.
7. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002; 94:2698-2705. (Pubitemid 34478086)
8. Berghoff A, Lassmann H, Preusser M, Hö ftberger R. Characterization of the inflammatory response to solid cancer metastases in the human brain. Clin Exp Metastasis 2012. [Epub ahead of print]
9. Kienast Y, von Baumgarten L, Fuhrmann M, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010; 16:116-122.
10. Preusser M, Winkler F, Laurence C, et al. Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. Eur J Cancer 2012. [Epub ahead of print]
11. Preusser M, de Ribaupierre S, Wohrer A, et al. Current concepts and management of glioblastoma. Ann Neurol 2011; 70:9-21.
12. Wen PY, Schiff D, Cloughesy TF, et al. It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol 2011; 29:3211-3213.
13. Maringwa J, Quinten C, King M, et al. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann Oncol 2012;22:2107-2112.
14. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526.
15. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
16. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13:459-465.
17. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012; 123:223-233.
18. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
19. Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N Engl J Med 2011; 365:2439-2441.
20. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012; 379:1893-1901.
21. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380:358-365.
22. Carlino MS, Fogarty GB, Long GV. Treatment of melanoma brain metastases: a new paradigm. Cancer J 2012; 18:208-212.
23. Kuhn J, Robins H, MehtaM. Tumor sequestration of lapatinib (NABTC 04-01). Neuro-Oncology 2008; 10:783.
24. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15:1452-1459.
25. Burstein HJ, Storniolo AM, Franco S, et al. A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008; 19:1068-1074. (Pubitemid 351796331)
26. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124-1130.
27. Sutherland S, Ashley S, Miles D, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases: the UK experience. Br J Cancer 2010; 102:995-1002.
28. Metro G, Foglietta J, Russillo M, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011; 22:625-630.
29. Lin NU, Eierman W, Greil R, et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 2011; 105:613-620.
30. Bachelot TD, Romieu G, Campone M, et al. LANDSCAPE: an FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (p) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR). J Clin Oncol 2011; 29(suppl.): abstract 509.
31. Porta R, Sanchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011; 37:624-631.
32. Eichler AF, Kahle KT, Wang DL, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro-Oncology 2010; 12:1193-1199.
33. Masuda T, Hattori N, Hamada A, et al. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol 2011; 67:1465-1469.
34. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011; 29:e443-e445.
35. Heon S, Yeap BY, Lindeman N, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced nonsmall cell lung cancer with EGFR mutations. Clin Cancer Res 2012; 18:4406-4414.
36. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 2012; 48:2192-2202.
37. Gril B, Palmieri D, Qian Y, et al. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2p breast cancer brain metastasis. Clin Cancer Res 2011; 17:142-153.
38. Duchnowska R, Biernat W, Szostakiewicz B, et al. Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2p advanced breast cancer patients receiving trastuzumab-containing therapy. Oncologist 2012; 17:26-35.
39. Duchnowska R, Jassem J, Thorat M. Gene expression analysis for prediction of early brain metastasis in HER2-positive breast cancer patients. J Clin Oncol 2008; 26(suppl.):abstract 1019.
40. Carbonell WS, Ansorge O, Sibson N, Muschel R. The vascular basement membrane as 'soil' in brain metastasis. PLoS One 2009; 4:e5857.